Dr. Mookerjee

Bijoyesh P. Mookerjee, MD

Contact Dr. Mookerjee

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours
  2. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib
  3. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer
  4. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
  5. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
  6. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
  7. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
  8. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
  9. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
  10. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
  11. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial
  12. Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms
  13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): Results of a phase 3, open-label, randomised trial
  14. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial
  15. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  16. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study
  17. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)
  18. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
  19. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  20. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease